{
    "2020-07-09": [
        [
            {
                "time": "",
                "orginal_text": "控股东被申请破产:曾疯狂并购 誉衡药业断臂求生还有戏吗？ 减资破产",
                "features": {
                    "keywords": [
                        "控股股东",
                        "破产",
                        "并购",
                        "誉衡药业"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "金融",
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "orginal_text": "恒瑞医药获沪股通连续7日净买入累计净买入16.40亿元",
                "features": {
                    "keywords": [
                        "恒瑞医药",
                        "沪股通",
                        "净买入"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "orginal_text": "20家药企，将接受现场检查",
                "features": {
                    "keywords": [
                        "药企",
                        "现场检查"
                    ],
                    "sentiment_score": -0.5,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "orginal_text": "恒瑞入局抗病毒领域，与国际巨头争抢百亿美元市场",
                "features": {
                    "keywords": [
                        "恒瑞",
                        "抗病毒",
                        "国际市场"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "orginal_text": "中国股市：未来十年，是科技的时代！板块龙头、全球以及国内第一",
                "features": {
                    "keywords": [
                        "中国股市",
                        "科技",
                        "板块龙头"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "科技"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "orginal_text": "PD-1耐药性有望解决！TIM-3靶点获批临床，恒瑞、BMS、罗氏最新进展",
                "features": {
                    "keywords": [
                        "PD-1",
                        "耐药性",
                        "TIM-3",
                        "恒瑞",
                        "BMS",
                        "罗氏"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "orginal_text": "高瓴火速再出手：这两家公司市值大涨170亿",
                "features": {
                    "keywords": [
                        "高瓴",
                        "市值",
                        "大涨"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "综合"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "orginal_text": "9日强势板块分析：软件医药股爆发 零售板块亮眼",
                "features": {
                    "keywords": [
                        "软件",
                        "医药",
                        "零售",
                        "板块"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "软件",
                        "医药",
                        "零售"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "orginal_text": "被纳入优先审评的10款重磅药物 达格列净片、维奈克拉片",
                "features": {
                    "keywords": [
                        "优先审评",
                        "重磅药物",
                        "达格列净片",
                        "维奈克拉片"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "orginal_text": "中信证券：药品研发国内巨头竞争优势明确 重点推荐恒瑞医药等",
                "features": {
                    "keywords": [
                        "中信证券",
                        "药品研发",
                        "恒瑞医药"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}